Compare Stocks

Alio Gold Inc., through its subsidiaries, engages in the acquisition, exploration, development, and operation of mineral resource properties. The company primarily mines for gold and silver. It holds 100% interests in San Francisco open pit gold mine that covers an area of approximately 53,380 hectares situated in the north central portion of the state of Sonora, Mexico; Florida Canyon open pit mine covering an area of approximately 11,886 hectares located in Nevada, the United States; and Ana Paula property situated in the state of Guerrero, Mexico. The company was formerly known as Timmins Gold Corp. and changed its name to Alio Gold Inc. in May 2017. Alio Gold Inc. was incorporated in 2005 and is headquartered in Vancouver, Canada.

Carmanah Technologies Corporation designs, develops, and distributes products focused on energy optimized light LED solutions for infrastructure worldwide. It operates in Signals and Illumination segments. The Signals segment provides solar LED flashing beacons, including pedestrian crosswalk signals, school zone flashers, and 24-hr roadway beacons for various roadway applications; a range of marine lighting solutions to coast guards, marine authorities, navies, and ports; and LED aviation lighting solutions, such as approach lightings, apron lightings, and solar and hybrid power systems. This segment also offers LED obstruction lighting solutions for aviation hazard marking, barricade lighting, way-finding, railway blue flag protection, equipment marking, and others; and navigation solutions on offshore wind farms for temporary and permanent marking. In addition, it provides devices to enable remote monitoring of assets. The Illumination segment offers LED lighting systems for off-grid lighting applications, including street, parking lot, park, and pathway applications. The company operates in North America, Europe, South America, the Middle East, Africa, and the Asia Pacific. Carmanah Technologies Corporation was incorporated in 1996 and is headquartered in Victoria, Canada.

VAALCO Energy, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids in Gabon, Egypt, Equatorial Guinea, and Canada. The company holds 58.8% interest in the Etame production sharing contract related to the Etame Marin block covering an area of approximately 46,200 gross acres located offshore in the Republic of Gabon in West Africa. It also owns 100% interest in the Eastern Desert, which contains West Gharib, West Bakr and North West Gharib merged concessions covering as area of approximately 45,067 acres, as well as Western Desert, which contains the South Ghazalat concession covering as area of approximately 7,340 acres located in Egypt. In addition, the company production and working interests in Cardium light oil and Mannville liquids-rich gas assets covering as area of 47,400 gross acres located near the north of Calgary, Alberta; and an undeveloped block offshore Equatorial Guinea, West Africa. VAALCO Energy, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.